Financial Instruments and Fair Value Measurements (Tables)

12 Months Ended

Dec. 29, 2017

Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:



	December 29, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.4	$	24.0	$	11.4	$	—
Equity securities	22.7		22.7		—		—
Foreign exchange forward and option contracts	0.1		0.1		—		—
	$	58.2	$	46.8	$	11.4	$	—
Liabilities:
Deferred compensation liabilities	$	42.7	$	—	$	42.7	$	—
Contingent consideration and acquired contingent liabilities	246.4		—		—		246.4
Foreign exchange forward and option contracts	0.1		0.1		—		—
	$	289.2	$	0.1	$	42.7	$	246.4



	December 30, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	33.6	$	22.8	$	10.8	$	—
Foreign exchange forward and option contracts	0.7		0.7		—		—
	$	34.3	$	23.5	$	10.8	$	—
Liabilities:
Deferred compensation liabilities	$	32.5	$	—	$	32.5	$	—
Contingent consideration and acquired contingent liabilities	250.5		—		—		250.5
Foreign exchange forward and option contracts	3.4		3.4		—		—
	$	286.4	$	3.4	$	32.5	$	250.5

Schedule of Reconciliation of Changes in Fair Value of Contingent Consideration

The following table summarizes the fiscal 2017 activity for contingent considerations:



Balance at December 30, 2016	$	250.5
Acquisition date fair value of contingent consideration	57.0
Payments	(25.0		)
Accretion expense	5.3
Fair value adjustment	(41.4		)
Balance at December 29, 2017	$	246.4

Schedule of Carrying Amount and Fair Value of Long-term Debt

The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:



	December 29, 2017				December 30, 2016
	Carrying Value		Fair Value		Carrying Value		Fair Value
Level 1:
Variable-rate receivable securitization due July 2017	$	—	$	—	$	250.0	$	250.0
3.50% notes due April 2018	300.0		299.1		300.0		298.7
4.875% notes due April 2020	700.0		675.2		700.0		699.5
Variable-rate receivable securitization due July 2020	200.0		200.0		—		—
5.75% notes due August 2022	884.0		804.8		884.0		850.3
4.75% notes due April 2023	526.5		412.4		600.0		520.9
5.625% notes due October 2023	738.0		628.8		738.0		682.4
5.50% notes due April 2025	692.1		564.5		695.0		615.7
Revolving credit facility	900.0		900.0		100.0		100.0
Level 2:
Term loans due March 2021	—		—		1,948.5		1,953.2
9.50% debentures due May 2022	10.4		10.9		10.4		12.0
8.00% debentures due March 2023	4.4		4.4		4.4		4.9
Term loan due September 2024	1,851.2		1,848.7		—		—
Level 3:
4.00% term loan due February 2022	—		—		6.5		6.5

Schedules of Concentration of Risk

The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales:



	Fiscal Year Ended						Three Months Ended
	December 29, 2017		September 30, 2016		September 25, 2015		December 30, 2016
CuraScript, Inc.	40	%	38	%	35	%	43	%
McKesson Corporation	*		12	%	20	%	10	%
AmerisourceBergen Corporation	*		*		10	%	*
Cardinal Health, Inc.	*		*		11	%	*

* Net sales to these distributors were less than 10% of total net sales during the respective periods presented above.

The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period:



	December 29, 2017		December 30, 2016
McKesson Corporation	26	%	28	%
AmerisourceBergen Corporation	15	%	15	%
CuraScript, Inc.	14	%	15	%
Cardinal Health, Inc.	11	%	10	%

The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales:



	Fiscal Year Ended						Three Months Ended
	December 29, 2017		September 30, 2016		September 25, 2015		December 30, 2016
H.P. Acthar Gel	37	%	34	%	35	%	39	%
Inomax	16	%	14	%	6	%	14	%